CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
TAVARLINdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00575146
NCT00575146Phase 1Completed
CompareCT.gov

Ketogenic Diet for Patients With Recurrent Glioblastoma

University Hospital Tuebingen·interventional·Posted Dec 18, 2007·Updated May 2, 2014

In Brief

A Phase 1 clinical trial evaluating TAVARLIN for Recurrent Glioblastoma. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma
CountriesGermany
CollaboratorsEvomed MedizinService GmbH

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 18, 2007
Enrollment StartDec 1, 2007
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.5 years ago

Interventions

TAVARLINdietary

ketogenic diet, dietary supplementary products provided by TAVARLIN